This segment focuses on the research and development of allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) for the treatment of various cancers. Key activities include genetic engineering of iPSCs to create chimeric antigen receptor (CAR)-iNK and CAR-iT cells that target specific tumor antigens. The segment's lead product candidate, CNTY-101, is undergoing Phase 1 trials for relapsed/refractory B-cell lymphoma. Other pipeline programs include CNTY-102 (CD19+CD22 CAR-iT) and CNTY-107 (Nectin-4 CAR-iT) targeting B-cell malignancies and solid tumors, respectively. The goal is to develop off-the-shelf cell therapies that can provide effective and accessible treatment options for a broad range of cancer patients, overcoming the limitations of autologous cell therapies. Future opportunities include expanding the pipeline with novel targets and enhancing cell therapy efficacy through advanced engineering techniques.

This segment is dedicated to leveraging Century Therapeutics' iPSC-derived allogeneic cell therapy platform for the treatment of autoimmune diseases. The approach involves engineering iNK cells to modulate the immune system and address the underlying causes of autoimmune disorders. A key program in this segment is the investigator-initiated Phase 1/2 trial of CNTY-101 in B-cell mediated autoimmune diseases. This research aims to demonstrate the potential of allogeneic iNK cell therapy to provide durable remissions and improve patient outcomes in autoimmune conditions. Future opportunities include expanding the pipeline with additional cell therapy candidates targeting different autoimmune pathways and exploring combination therapies to enhance efficacy. The segment's success will depend on demonstrating safety and efficacy in clinical trials and establishing a competitive advantage over existing treatments.